The term Pinch-2 inhibitors refers to a class of chemical compounds designed to target and inhibit the protein known as Pinch-2 (particularly known as LIMS1 or LIM and SH3 domain protein 1). Pinch-2 is a critical component of cellular adhesion complexes, playing a pivotal role in the regulation of cell adhesion, migration, and signal transduction. These inhibitors are primarily developed for research purposes, aiming to dissect the intricate molecular mechanisms that govern cell adhesion and migration. Pinch-2, a cytoskeletal adaptor protein, is associated with integrins and various signaling molecules, acting as a bridge between the extracellular matrix and the intracellular cytoskeleton. It plays a crucial role in orchestrating cellular processes such as cell adhesion, spreading, and migration by mediating the transmission of mechanical and chemical signals.
Pinch-2 inhibitors are synthetic or naturally derived compounds specifically designed to disrupt the interactions involving Pinch-2, often by binding to its functional domains or critical binding sites. By doing so, these inhibitors enable researchers to investigate the roles of Pinch-2 in various cellular processes and the downstream consequences of its inhibition.These compounds have been instrumental in advancing our understanding of cellular adhesion and migration mechanisms, shedding light on the intricate interplay between extracellular cues and intracellular signaling pathways. Researchers utilize Pinch-2 inhibitors in cell culture and experimental models to explore the fundamental processes underlying cell behavior, tissue development, and disease progression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib targets CDK4/6, preventing the phosphorylation of Rb protein and halting the progression of the cell cycle in hormone receptor-positive breast cancer. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is another CDK4/6 inhibitor, disrupting the cell cycle by inhibiting Rb phosphorylation and promoting cell cycle arrest. | ||||||
BYL719 | 1217486-61-7 | sc-391001 sc-391001A sc-391001B sc-391001C sc-391001D sc-391001E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $391.00 $597.00 $755.00 $1192.00 $5000.00 $9370.00 | 2 | |
Alpelisib is a PI3K inhibitor that selectively inhibits the p110α isoform of PI3K, interfering with the PI3K/Akt/mTOR signaling pathway frequently dysregulated in cancer. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
Idelalisib targets the delta isoform of PI3K, blocking signaling pathways involved in B-cell proliferation and survival, making it useful in certain lymphomas. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that interferes with B-cell receptor signaling, making it valuable in B-cell malignancies. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib is another BTK inhibitor, disrupting B-cell receptor and cytokine signaling pathways. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK) inhibitor that hinders cytokine signaling. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Baricitinib inhibits JAK1 and JAK2, reducing the immune response in autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus. | ||||||